128 related articles for article (PubMed ID: 3940216)
1. CB 1954 revisited. I. Disposition kinetics and metabolism.
Workman P; White RA; Talbot K
Cancer Chemother Pharmacol; 1986; 16(1):1-8. PubMed ID: 3940216
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
Kestell P; Pruijn FB; Siim BG; Palmer BD; Wilson WR
Cancer Chemother Pharmacol; 2000; 46(5):365-74. PubMed ID: 11127940
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics of benznidazole.
Workman P; White RA; Walton MI; Owen LN; Twentyman PR
Br J Cancer; 1984 Sep; 50(3):291-303. PubMed ID: 6466543
[TBL] [Abstract][Full Text] [Related]
6. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
Workman P
Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
[TBL] [Abstract][Full Text] [Related]
7. CB 1954 revisited. II. Toxicity and antitumour activity.
Workman P; Morgan JE; Talbot K; Wright KA; Donaldson J; Twentyman PR
Cancer Chemother Pharmacol; 1986; 16(1):9-14. PubMed ID: 3940225
[TBL] [Abstract][Full Text] [Related]
8. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
Feun LG; Savaraj N; Lu K; Guo Z; Raulston LG; Benjamin RS; Fields WS; Loo TL
J Neurooncol; 1983; 1(3):219-24. PubMed ID: 6678971
[TBL] [Abstract][Full Text] [Related]
9. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Spiegel JF; Egorin MJ; Collins JM; Lerner BD; Bachur NR
Drug Metab Dispos; 1983; 11(1):41-6. PubMed ID: 6132794
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of diaziquone after three different dosage regimens.
Bjornsson TD; Schold SC; Friedman HS; Schneider D; Falletta JM
Cancer Treat Rep; 1985 Dec; 69(12):1383-5. PubMed ID: 4075314
[TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
Workman P; Binger M; Kooistra KL
Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-induced aziridine formation by rat liver microsomes.
Hata Y; Watanabe M
Biochem Biophys Res Commun; 1983 Jan; 110(1):220-7. PubMed ID: 6838512
[TBL] [Abstract][Full Text] [Related]
14. The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).
Jarman M; Melzack DH; Ross WC
Biochem Pharmacol; 1976 Nov; 25(22):2475-8. PubMed ID: 985569
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
Evans SM; Young D; Robertson IG; Paxton JW
Cancer Chemother Pharmacol; 1992; 31(1):32-6. PubMed ID: 1458557
[TBL] [Abstract][Full Text] [Related]
17. A new metabolic reaction of diaziridines by rat liver microsomes.
Hata Y; Watanabe M
Biochem Biophys Res Commun; 1982 May; 106(2):526-32. PubMed ID: 7104007
[No Abstract] [Full Text] [Related]
18. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems II: comparative pharmacokinetics in dogs.
Lalka D; Jusko WJ; Bardos TJ
J Pharm Sci; 1975 Feb; 64(2):230-5. PubMed ID: 236372
[No Abstract] [Full Text] [Related]
19. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
Egorin MJ; Bellis EH; Salcman M; Collins JM; Spiegel JF; Bachur NR
J Neurosurg; 1984 May; 60(5):1005-13. PubMed ID: 6716135
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
